The Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Most Body Mass Index Categories in Type 2 Diabetes: Results of the LEADER and SUSTAIN 6 Trials

被引：0
|
作者：
Verma, Subodh [1 ]
Bain, Stephen [2 ]
Bhatt, Deepak L. [3 ,4 ]
Leiter, Lawrence A. [5 ]
Mazer, C. David [6 ]
McGuire, Darren K. [7 ]
Pratley, Richard [8 ]
Zinman, Bernard [9 ]
Lindberg, Sore [10 ]
Rasmussen, Soren [11 ]
Vrazic, Hrvoje [12 ]
Buse, John [13 ]
机构：
[1] St Michaels Hosp, Div Cardiac Surg, Toronto, ON, Canada
[2] Swansea Univ, Inst Life Sci, Swansea, W Glam, Wales
[3] Brigham & Womens Hosp, Heart & Vasc Ctr, Intervent Cardiovasc Programs, 75 Francis St, Boston, MA 02115 USA
[4] Harvard Med Sch, Boston, MA 02115 USA
[5] St Michaels Hosp, Div Endocrinol & Metab, Toronto, ON, Canada
[6] St Michaels Hosp, Keenan Rsch Ctr Biomed Sci, Toronto, ON, Canada
[7] Univ Texas Southwestern Med Ctr Dallas, Div Cardiol, Dallas, TX 75390 USA
[8] Florida Hosp, Translat Rsch Inst Metab & Diabet, Orlando, FL USA
[9] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Rsch Inst, Med, Toronto, ON, Canada
[10] Novo Nordisk AS, Med & Sci, Soborg, Denmark
[11] Novo Nordisk AS, Biostat GLP 1 Diabet, Soborg, Denmark
[12] Novo Nordisk AS, GLP 1 Outcomes & Liraglutide Diabet, Soborg, Denmark
[13] Univ N Carolina, Sch Med, Div Endocrinol, Chapel Hill, NC 27515 USA
来源：
CIRCULATION | 2018年 / 138卷
关键词：
Body mass index (BMI) and waist circumference; Cardiorenal; Cardiovascular disease; Cardiovascular disease prevention; Diabetes (Type II);
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A14806
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of theLEADERandSUSTAIN6 trials
    Verma, Subodh
    McGuire, Darren K.
    Bain, Stephen C.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    Mazer, C. David
    Monk Fries, Tea
    Pratley, Richard E.
    Rasmussen, Soren
    Vrazic, Hrvoje
    Zinman, Bernard
    Buse, John B.
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (12): : 2487 - 2492
  • [2] The Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Baseline Blood Pressure Categories: Analysis of LEADER and SUSTAIN 6
    Leiter, Lawrence A.
    Bain, Stephen
    Bhatt, Deepak L.
    Buse, John
    Mazer, C. David
    Pratley, Richard
    Lindberg, Soren
    Rasmussen, Soren
    Vrazic, Hrvoje
    Verma, Subodh
    [J]. CIRCULATION, 2018, 138
  • [3] The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
    Leiter, Lawrence A.
    Bain, Stephen C.
    Bhatt, Deepak L.
    Buse, John B.
    Mazer, C. David
    Pratley, Richard E.
    Rasmussen, Soren
    Ripa, Maria Sejersten
    Vrazic, Hrvoje
    Verma, Subodh
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (09): : 1690 - 1695
  • [4] Liraglutide and semaglutide improve cardiovascular and renal outcomes across most BMI categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials
    Verma, S.
    Bain, S. C.
    Bhatt, D. L.
    Leiter, L. A.
    Mazer, C. D.
    McGuire, D. K.
    Pratley, R.
    Zinman, B.
    Lindberg, S.
    Rasmussen, S.
    Vrazic, H.
    Buse, J. B.
    [J]. DIABETOLOGIA, 2019, 62 : S560 - S560
  • [5] Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
    Shaman, Ahmed M.
    Bain, Stephen C.
    Bakris, George L.
    Buse, John B.
    Idorn, Thomas
    Mahaffey, Kenneth W.
    Mann, Johannes F. E.
    Nauck, Michael A.
    Rasmussen, Soren
    Rossing, Peter
    Wolthers, Benjamin
    Zinman, Bernard
    Perkovic, Vlado
    [J]. CIRCULATION, 2022, 145 (08) : 575 - 585
  • [6] EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES - A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS
    Perkovic, Vlado
    Bain, Stephen
    Bakris, George
    Buse, John
    Idorn, Thomas
    Mahaffey, Kenneth
    Marso, Steven
    Nauck, Michael
    Pratley, Richard
    Rasmussen, Soren
    Rossing, Peter
    Tornoe, Karen
    Zinman, Bernard
    Mann, Johannes
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 : 338 - 338
  • [7] Liraglutide and semaglutide improve cardiovascular and renal outcomes across baseline BP categories: analysis of LEADER and SUSTAIN 6
    Leiter, L. A.
    Bain, S. C.
    Bhatt, D. L.
    Buse, J. B.
    Mazer, C. D.
    Pratley, R.
    Lindberg, S.
    Rasmussen, S.
    Vrazic, H.
    Verma, S.
    [J]. DIABETOLOGIA, 2019, 62 : S364 - S365
  • [8] The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
    Win L. Yin
    Steve C. Bain
    Thinzar Min
    [J]. Diabetes Therapy, 2020, 11 : 835 - 844
  • [9] The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
    Yin, Win L.
    Bain, Steve C.
    Min, Thinzar
    [J]. DIABETES THERAPY, 2020, 11 (04) : 835 - 844
  • [10] Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes
    Mosenzon, Ofri
    Schechter, Meir
    Leibowitz, Gil
    [J]. ADVANCES IN CHRONIC KIDNEY DISEASE, 2021, 28 (04) : 347 - 360
12345